UBS lowered the firm’s price target on CVS Health (CVS) to $94 from $102 and keeps a Buy rating on the shares. UBS says CVS sentiment is "weary," and that the key debate is what 2023/2024 earnings will be, as existing guidance of $8.70-$8.90 and $9.00 is perceived to be at risk from a potential earlier close of the Oak Street Health (OSH) deal, the MA rate notice and lower COVID revenues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVS:
- CVS Slips on Guidance Cut
- CVS HEALTH REPORTS FIRST QUARTER RESULTS, COMPLETES ACQUISITIONS OF SIGNIFY HEALTH AND OAK STREET HEALTH
- CVS Health completes acquisition of Oak Street Health
- CVS Health price target lowered to $93 from $107 at Bernstein
- Cigna price target lowered to $293 from $367 at Bernstein